The TGF-B1 and IL-10 gene polymorphisms are associated with risk of developing silent myocardial ischemia in the diabetic patients
The TGF-B1 and IL-10 gene polymorphisms are associated with risk of developing silent myocardial ischemia in the diabetic patients
复制标题
DOI：
10.1016/j.imlet.2013.09.007
复制
发表时间：
2013-11-01
影响因子：
4.4
通讯作者：
Vargas-Alarcon, Gilberto
中科院分区：
文献类型：
--
作者：
Cruz, Miguel;Manuel Fragoso, Jose;Vargas-Alarcon, Gilberto
无症状性心肌缺血（SMI）是一种多因素、多基因的疾病，由过度的炎症反应引起。考虑到IL-10和TGF-β 1作为炎症过程和血管生理学调节剂的突出作用，本研究的目的是分析IL-10和TGF-β 1单核苷酸多态性（SNP）是否与SMI相关。IL-10-1082 A>G（rs1800896），IL-10-819 T>C（rs1800871），IL-10-592 A>C（rs1800872），TGF-β 1-509 T>C在149名SMI患者和248名健康对照组中，通过5 '核酸外切酶TaqMan基因分型分析来分析TGF-β 1 T29 C（rs 1800470）SNP。在显性和杂合模型下，与对照相比，IL-10-1082 A>G（rs 1800896）SNP与SMI风险增加显著相关（OR = 1.77，P-dom = 0.029和OR = 1.69，P-Het = 0.043）。另一方面，在显性和加性模型下，与对照组相比，TGF-β 1 509 T>C（rs 1800469）SNP与SMI风险增加显著相关（OR = 1.82，P-dom = 0.035，OR = 1.50，P-add = 0.026）。最后，TGF-β 1 T29 C在共显性、显性、隐性和加性模型下，与对照组相比，（rs 1800470）SNP与SMI风险增加显著相关（OR = 3.63，P-Cod = 0.004，OR = 2.24，P-dom = 0.002，OR = 2.46，P-rec = 0.03和OR = 1.94，P-add = 0.001）。校正性别、年龄和吸烟后，两种单倍型（CC和TT）与SMI风险降低相关（OR = 0.26，PG（rs 1800896）、TGF-β 1-509 T>C（rs 1800469）和TGF-β 1，91 T29 C（rs 1800470）SNP在发生SMI的风险中起重要作用。在我们的研究中，有可能区分两种保护性单倍型TGF-β 1 SMI的发展。(C)2013爱思唯尔有限公司版权所有。
Silent myocardial ischemia (SMI) is a multifactorial and polygenic disorder that results from an excessive inflammatory response. Considering the prominent role of IL-10 and TGF-B1 as regulators of the inflammatory process and vascular physiology, the aim of the present study was to analyze whether IL-10 and TGF-B1 single nucleotide polymorphisms (SNPs) are associated with SMI. The IL-10-1082 A>G (rs1800896), IL-10-819 T>C (rs1800871), IL-10-592 A>C (rs1800872), TGF-beta 1-509 T>C (rs1800469), and TGF-beta 1 T29C (rs1800470) SNPs were analyzed by 5'exonuclease TaqMan genotyping assays in a group of 149 SMI patients and 248 healthy controls. The IL-10-1082 A>G (rs1800896) SNP was significantly associated with an increased risk of SMI as compared to controls under both dominant and heterozygous models (OR = 1.77, P-dom = 0.029 and OR = 1.69, P-Het = 0.043). On the other hand, the TGF-beta 1 509 T>C (rs1800469) SNP was significantly associated with increased risk of SMI as compared to controls under a dominant and additive models (OR = 1.82, P-dom = 0.035, OR = 1.50, P-add = 0.026). Finally, the TGF-beta 1 T29C(rs1800470) SNP was significantly associated with increased risk of SMI as compared to controls under a co-dominant, dominant, recessive, and additive models (OR = 3.63, P-Cod = 0.004, OR = 2.24, P-dom = 0.002, OR = 2.46, P-rec = 0.03 and OR = 1.94, P-add = 0.001). After adjusted for gender, age, and smoking, two haplotypes (CC and TT) were associated with decreased risk of SMI (OR = 0.26, PG (rs1800896), TGF-beta 1-509 T>C (rs1800469), and TGF-beta 1,91 T29C (rs1800470) SNPs play an important role in the risk of developing SMI. In our study, it was possible to distinguish two protective haplotypes in TGF-beta 1 for SMI development. (C) 2013 Elsevier B.V. All rights reserved.